$0.90
4.77%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
US84833T1034
Symbol
SPRO

Spero Therapeutics, Inc. Stock News

Neutral
●
GlobeNewsWire
●
5 days ago
SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD) Cash and cash equivalents of $107.9 million as of September 30, 2026, expected to fund operations into the second half of 2029 CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clini...
Neutral
●
GlobeNewsWire
●
7 days ago
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases, today announced the appointment of William Ho, M.D.
Neutral
●
GlobeNewsWire
●
13 days ago
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on November 2, 2026, of an aggregate of 217,000 restricted stock unit awards (RSUs) ...
Neutral
●
GlobeNewsWire
●
22 days ago
Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapies Dae Gon Ha, Ph.D.
Neutral
●
GlobeNewsWire
●
about one month ago
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference to be held i...
Positive
●
Invezz
●
about one month ago
Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.
Neutral
●
GlobeNewsWire
●
about 2 months ago
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs)...
Neutral
●
GlobeNewsWire
●
3 months ago
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on September 1, 2026, of an aggregate of 102,000 restricted stock unit awards (R...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today